Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study
| Autor: | Keiichi Arakawa, Kenichi Sugihara, H. Nozawa, Keisuke Hata, Tsutomu Tanaka, Kazushige Kawai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Colorectal cancer Adjuvant chemotherapy medicine.medical_treatment Antineoplastic Agents Disease Stage ii Young Adult 03 medical and health sciences 0302 clinical medicine Japan Internal medicine medicine Humans In patient Stage (cooking) Aged Neoplasm Staging Retrospective Studies Aged 80 and over Chemotherapy business.industry Gastroenterology Retrospective cohort study Middle Aged Prognosis medicine.disease Hospitals Survival Rate Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Colorectal Neoplasms business |
| Zdroj: | Colorectal Disease. 20:O162-O172 |
| ISSN: | 1462-8910 |
| DOI: | 10.1111/codi.14260 |
| Popis: | AIM Clinical guidelines recommend adjuvant chemotherapy for high-risk patients with Stage II-III colorectal cancer. However, chemotherapeutic administration rates differ significantly between hospitals. We assessed the prognostic benefit of adjuvant chemotherapy in patients with Stage IIb/c colorectal cancer, and the prognostic impact of interhospital variations in the administration of adjuvant chemotherapy for Stage II-III colorectal cancer. METHOD We conducted a multicentre, retrospective study of 17 757 patients with Stage II-III colorectal cancer treated between 1997 and 2008 in 23 hospitals in Japan. Hospitals were classified as high-rate (rate > 42.8%) or low-rate (rate ≤ 42.8%), chemotherapy prescribing clinics. RESULTS The 5-year overall survival (OS) of patients with Stage II-III colorectal cancer receiving adjuvant chemotherapy was significantly higher than for those not receiving adjuvant chemotherapy (85.7% vs 79.2%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text